USA flag logo/image

An Official Website of the United States Government

TESTING ITS IMMUNOTHERAPEUTIC POTENTIAL THE LONG-TERM OBJECTIVE OF THIS PROJECT…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
3031
Program Year/Program:
1985 / SBIR
Agency Tracking Number:
3031
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
C-MOTION, INC.
C-MOTION, INC. 15821A CRABBS BRANCH WAY ROCKVILLE, MD 20855
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1985
Title: TESTING ITS IMMUNOTHERAPEUTIC POTENTIAL THE LONG-TERM OBJECTIVE OF THIS PROJECT IS TO DEVELOP PROCESSES FOR THE PRODUCTION OF B-CELL GROWTH FACTOR (BCGF) AND TO TEST THE POTENTIAL APPLICATIONS OF BCGF FOR THE TREATMENT OF HUMAN IMMUNOPATHOLOGICAL
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

TESTING ITS IMMUNOTHERAPEUTIC POTENTIAL THE LONG-TERM OBJECTIVE OF THIS PROJECT IS TO DEVELOP PROCESSES FOR THE PRODUCTION OF B-CELL GROWTH FACTOR (BCGF) AND TO TEST THE POTENTIAL APPLICATIONS OF BCGF FOR THE TREATMENT OF HUMAN IMMUNOPATHOLOGICAL CONDITIONS. BCGF MAY BE USEFUL AS AN IMMUNOTHERAPEUTIC AGENT IN THE TREATMENT OF PRIMARY IMMUNODEFICIENCY DISEASES AND POSSIBLY IN CERTAIN B-CELL LEUKEMIAS. THE PRINCIPAL GOAL OF THE FIRST PHASE OF THIS PROJECT IS TO DEVELOP A CONTINUOUS B-CELL LINE WHICH CAN BE USED TO FACILITATE THE LARGE-SCALE PURIFICATION OF BCGF. FRESHLY ISOLATED B CELLS FROM NORMAL HUMAN DONORS WILL BE PLACED INTO AN INITIAL SUSPENSION CULTURE. CULTURED CELLS WILL THEN BE CLONED IN SOFT AGAR AND RECLONED BY LIMITING DILUTION. B-CELL LINES WILL BE MAINTAINED WITH PARTIALLY PURIFIED BCGF ALREADY DEVELOPED AT COLLABORATIVE RESEARCH. IT IS ANTICIPATED THAT A BCGF-DEPENDENT CELL LINE WILL BE DEVELOPED DURING PHASE I. THIS LINE WILL BE USED TO DEVELOP A SIMPLE, RAPID AND REPRODUCIBLE ASSAY FOR THE DETECTION OF BCGF. IN PHASE II, METHODS WILL BE DEVELOPED TO PURIFY BCGF IN AMOUNTS SUFFICIENT FOR BIOCHEMICAL/BIOLOGICAL CHARACTERIZATION STUDIES AND FOR EVENTUAL CLINICAL EVALUATION AS AN IMMUNOAUGMENTATIVE AGENT IN THE TREATMENT OF IMMUNODEFICIENCY DISEASES AND B-CELL LEUKEMIAS.

Principal Investigator:

Susan k. keesee
PRINCIPAL INVESTIGATOR
6178619700

Business Contact:

Small Business Information at Submission:

Collaborative Research Inc
128 Spring St. Lexington, MA 02173

EIN/Tax ID: 522053087
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No